skip to Main Content

So finden Sie uns!

Das Westdeutsche Herz- und Gefäßzentrum Essen mit der Klinik für Kardiologie und Angiologie befindet sich auf dem Gelände des Universitätsklinikums Essen. Sollten Sie die Routenplanung selbst vornehmen wollen, dann schauen Sie unsere Wegbeschreibung oder benutzen Sie bitte folgende Postadresse:

Hufelandstr. 55 | 45122 Essen

Bleiben sie mit uns in Kontakt

Fax: +49 (201) 723 - 5480
Lageplan des Klinikums

Standort

E-Mail: martin.heisler@uk-essen.de
Office: MFZ 3. OG Room 03.026
Telefon: +49 201 723 6011
Fax: +49 201 723 6973
Dr. rer. nat. Martin Heisler

BIO

Martin Heisler received his M.Sc. in 2013 from the Ruhr University Bochum (RUB) in Biology with the specification in Bio­tech­nology. He performed his master thesis at the Institute of Pharmacology and Toxi­cology of RUB. In 2014 he started the re­search activity for his PhD thesis at the Department of Cardiology at the University Hospital Düsseldorf under supervision of Prof. Rassaf. Since August 2015, he joined the University Hospital Essen as a research member of the CardioScienceLabs at the Department of Cardiology. In 2018 he earned his Dr. rer. nat. at the University Essen-Duisburg, Faculty of Biology, under the mentorship of Prof. Rassaf.

RESEARCH INTERESTS

While early mortality in patients with acute myocardial infarction (AMI) has declined after enormous proceedings in cardiovascular healthcare, survivors remain at risk for development of heart failure due to insufficient healing after myocardial infarction. Macrophage Migration Inhibitory Factor (MIF) is a pleiotropic cytokine, shown to play an essential part in formation of innate immune reactions, especially in heart diseases.

My work focuses on the regulatory role of MIF in an innate immune response after myocardial ischemia/reperfusion, which amplitude and duration mainly determine healing.

In detail, I investigate the interaction of this cytokine with the activation of inflammatory leucocytes and their migration into the infarcted tissue. Targeting MIF could lead to an attenuated extent of this immune reaction, thus to an improved healing of the myocardium and thereby diminish the risk of developing heart failure after AMI.

PUBLICATIONS

  1. Luedike P, Rammos C, Pohl J, Heisler M, Totzeck M, Kleophas W, Hetzel GR, Kelm M, Hendgen-Cotta U, Rassaf T.  2015 – Filtration of Macrophage Migration Inhibitory Factor (MIF) in Patients with End Stage Renal Disease Undergoing Hemodialysis. PLoS One 10, e0140
  2. Pinto A, Speckmann B, Heisler M, Sies H, Steinbrenner H. 2011 – Delaying of insulin signal transduction in skeletal muscle cells by selenium compounds. J Inorg Biochem. 105, 812-820
Back To Top